Free Trial

Relay Therapeutics (RLAY) Stock Price, News & Analysis

Relay Therapeutics logo
$3.56 -0.13 (-3.41%)
As of 10:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Relay Therapeutics Stock (NASDAQ:RLAY)

Key Stats

Today's Range
$3.57
$3.74
50-Day Range
$3.19
$3.81
52-Week Range
$1.77
$10.72
Volume
213,440 shs
Average Volume
2.21 million shs
Market Capitalization
$614.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.08
Consensus Rating
Moderate Buy

Company Overview

Relay Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

RLAY MarketRank™: 

Relay Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 684th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Relay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Relay Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Relay Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.55) to ($2.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Relay Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Relay Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Relay Therapeutics has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Relay Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    13.65% of the float of Relay Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Relay Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Relay Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Relay Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Relay Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.65% of the float of Relay Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Relay Therapeutics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Relay Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Relay Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Relay Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    7 people have searched for RLAY on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $542,926.00 in company stock.

  • Percentage Held by Insiders

    Only 4.87% of the stock of Relay Therapeutics is held by insiders.

  • Percentage Held by Institutions

    96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Relay Therapeutics' insider trading history.
Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RLAY Stock News Headlines

What is HC Wainwright's Forecast for RLAY FY2026 Earnings?
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Headlines

RLAY Stock Analysis - Frequently Asked Questions

Relay Therapeutics' stock was trading at $4.12 at the start of the year. Since then, RLAY stock has decreased by 13.5% and is now trading at $3.5640.

Relay Therapeutics, Inc. (NASDAQ:RLAY) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.08. The company earned $0.70 million during the quarter, compared to the consensus estimate of $0.07 million.

Relay Therapeutics (RLAY) raised $250 million in an IPO on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

Relay Therapeutics' top institutional investors include Commodore Capital LP (7.74%), Bellevue Group AG (4.77%), JPMorgan Chase & Co. (2.52%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Brian Adams, Thomas Catinazzo and Andy Porter.
View institutional ownership trends
.

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/07/2025
Today
8/29/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RLAY
CIK
1812364
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

High Price Target
$24.00
Low Price Target
$4.00
Potential Upside/Downside
+363.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$337.71 million
Net Margins
N/A
Pretax Margin
-3,728.45%
Return on Equity
-41.49%
Return on Assets
-37.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
20.92
Quick Ratio
20.92

Sales & Book Value

Annual Sales
$8.36 million
Price / Sales
76.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.86 per share
Price / Book
0.96

Miscellaneous

Outstanding Shares
172,411,000
Free Float
164,015,000
Market Cap
$636.20 million
Optionable
Optionable
Beta
1.62

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:RLAY) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners